Literature DB >> 16787834

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

W Danysz1, C G Parsons, H J Mobius, A Stoffler, G Quack.   

Abstract

The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer's disease is finding increasingly more acceptance in the scientific community. Central to this hypothesis is the assumption that in particular glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner. Such continuous mild activation leads under chronic conditions to neuronal damage. Moreover, one should consider that impairment of plasticity (learning) may result not only from neuronal damage per se but also from continuous activation of NMDA receptors. To investigate this possibility we tested whether overactivation of NMDA receptors using either non-toxic doses/concentrations of a direct NMDA agonist or through an indirect approach--decrease in magnesium concentration--produces deficits in plasticity. In fact NMDA both in vivo (passive avoidance test) and in vitro (LTP in CA1 region) impaired learning and synaptic plasticity. Under these conditions memantine which is an uncompetitive NMDA receptor antagonist with features of "improved magnesium" (voltage dependence, affinity) attenuated the deficit. The more direct proof that memantine can act as a surrogate for magnesium was obtained in LTP experiments under low magnesium conditions. In this case as well, impaired LTP was restored in the presence of therapeutically relevant concentrations of memantine (1 microM). In vivo, doses leading to similar brain/serum levels produce neuroprotection in animal models relevant for neurodegeneration in Alzheimer's disease such as neurotoxicity produced by inflammation in the NBM or beta-amyloid injection to the hippocampus. Hence, we postulate that if in Alzheimer's disease overactivation of NMDA receptors occurs indeed, memantine would be expected to improve both symptoms (cognition) and slow down disease progression because it takes over the physiological function of magnesium.

Entities:  

Year:  2000        PMID: 16787834     DOI: 10.1007/bf03033787

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  59 in total

1.  Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis.

Authors:  M Y Globus; R Busto; W D Dietrich; E Martinez; I Valdes; M D Ginsberg
Journal:  J Neurochem       Date:  1988-11       Impact factor: 5.372

2.  beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus.

Authors:  J Wu; R Anwyl; M J Rowan
Journal:  Neuroreport       Date:  1995-11-27       Impact factor: 1.837

3.  Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity.

Authors:  P Couratier; M Lesort; P Sindou; F Esclaire; C Yardin; J Hugon
Journal:  Mol Chem Neuropathol       Date:  1996-04

Review 4.  Contributory mechanisms in the causation of neurodegenerative disorders.

Authors:  G J Lees
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

5.  Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance.

Authors:  M. Misztal; W. Danysz
Journal:  Behav Pharmacol       Date:  1995-08       Impact factor: 2.293

6.  Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists.

Authors:  P Couratier; P Sindou; F Tabaraud; A G Diop; P S Spencer; J Hugon
Journal:  Neurodegeneration       Date:  1995-03

7.  Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

Authors:  R Töpper; J Gehrmann; R Banati; M Schwarz; F Block; J Noth; G W Kreutzberg
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease.

Authors:  E Masliah; M Mallory; M Alford; S Tanaka; L A Hansen
Journal:  J Neuropathol Exp Neurol       Date:  1998-11       Impact factor: 3.685

9.  Low concentrations of N-methyl-D-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices.

Authors:  Y Izumi; D B Clifford; C F Zorumski
Journal:  Neurosci Lett       Date:  1992-03-30       Impact factor: 3.046

10.  The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation.

Authors:  J R Brorson; V P Bindokas; T Iwama; C J Marcuccilli; J C Chisholm; R J Miller
Journal:  J Neurobiol       Date:  1995-03
View more
  45 in total

1.  Emerging Therapeutic Strategies for Treating Alzheimer's Disease in Primary Care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-12

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 3.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 5.  Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.

Authors:  T Heinen-Kammerer; H Rulhoff; S Nelles; R Rychlik
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

6.  Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.

Authors:  G G Neznamov; E S Teleshova
Journal:  Neurosci Behav Physiol       Date:  2009-03

7.  Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Authors:  Miren Ettcheto; Elena Sánchez-López; Yaiza Gómez-Mínguez; Henrry Cabrera; Oriol Busquets; Carlos Beas-Zarate; Maria Luisa García; Eva Carro; Gemma Casadesus; Carme Auladell; Manuel Vázquez Carrera; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

Review 8.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease.

Authors:  Rui Wang; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  The effects of the glutamate antagonist memantine on brain activation to an auditory perception task.

Authors:  Heidi van Wageningen; Hugo A Jørgensen; Karsten Specht; Tom Eichele; Kenneth Hugdahl
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

10.  Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo.

Authors:  Tadeusz Frankiewicz; Chris G Parsons
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.